The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dalyot-Herman, N.
Right arrow Articles by Malek, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dalyot-Herman, N.
Right arrow Articles by Malek, T. R.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Dietary Proteins
The Journal of Immunology, 2000, 165: 6731-6737.
Copyright © 2000 by The American Association of Immunologists

Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC1

Nava Dalyot-Herman*, Oliver F. Bathe{dagger} and Thomas R. Malek2,*

* Department of Microbiology and Immunology and {dagger} Department of Surgery, Division of Surgical Oncology, University of Miami School of Medicine, Miami,FL 33101

In the present report, we have studied the potential of naive and activated effector CD8+ T cells to function as anti-tumor T cells to a solid tumor using OVA-specific T cells from TCR-transgenic OT-I mice. Adoptive transfer of naive OT-I T cells into tumor-bearing syngeneic mice did not inhibit tumor cell growth. The adoptively transferred OT-I T cells did not proliferate in lymphoid tissue of tumor-bearing mice and were not anergized by the tumor. In contrast, adoptive transfer of preactivated OT-I CTL inhibited tumor growth in a dose-dependent manner, indicating that E.G7 was susceptible to immune effector cells. Importantly, naive OT-I T cells proliferated and elicited an anti-tumor response if they were adoptively transferred into normal or CD4-deficient mice that were then vaccinated with GM-CSF-induced bone marrow-derived OVA-pulsed APC. Collectively, these data indicate that even though naive tumor-specific T cells are present at a relatively high fraction they remain ignorant of the tumor and demonstrate that a CD8-mediated anti-tumor response can be induced by Ag-pulsed APC without CD4 T cell help.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Wakabayashi, Y. Nakagawa, M. Shimizu, K. Moriya, Y. Nishiyama, and H. Takahashi
Suppression of an Already Established Tumor Growing through Activated Mucosal CTLs Induced by Oral Administration of Tumor Antigen with Cholera Toxin
J. Immunol., March 15, 2008; 180(6): 4000 - 4010.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor
J. Immunol., June 1, 2007; 178(11): 6752 - 6760.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. Hollenbaugh and R. W. Dutton
IFN-{gamma} Regulates Donor CD8 T Cell Expansion, Migration, and Leads to Apoptosis of Cells of a Solid Tumor.
J. Immunol., September 1, 2006; 177(5): 3004 - 3011.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Lou, G. Wang, G. Lizee, G. J. Kim, S. E. Finkelstein, C. Feng, N. P. Restifo, and P. Hwu
Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo
Cancer Res., September 15, 2004; 64(18): 6783 - 6790.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Boissonnas, C. Combadiere, E. Lavergne, M. Maho, C. Blanc, P. Debre, and B. Combadiere
Antigen Distribution Drives Programmed Antitumor CD8 Cell Migration and Determines Its Efficiency
J. Immunol., July 1, 2004; 173(1): 222 - 229.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Carrio, O. F. Bathe, and T. R. Malek
Initial Antigen Encounter Programs CD8+ T Cells Competent to Develop into Memory Cells That Are Activated in an Antigen-Free, IL-7- and IL-15-Rich Environment
J. Immunol., June 15, 2004; 172(12): 7315 - 7323.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor
Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens
Cancer Res., December 15, 2003; 63(24): 9007 - 9015.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, M. I. Nishimura, and D. J. Cole
Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity
J. Immunol., February 1, 2003; 170(3): 1209 - 1217.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Goldberg, P. Shrikant, and M. F. Mescher
In Vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)
J. Immunol., January 1, 2003; 170(1): 228 - 235.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, and D. J. Cole
Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells
J. Immunol., November 1, 2002; 169(9): 4928 - 4935.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. F. Bathe, N. Dalyot-Herman, and T. R. Malek
IL-2 During In Vitro Priming Promotes Subsequent Engraftment and Successful Adoptive Tumor Immunotherapy by Persistent Memory Phenotypic CD8+ T Cells
J. Immunol., October 15, 2001; 167(8): 4511 - 4517.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.